Tarek K. Rajji, MD

University of Toronto, Toronto, Ontario, Canada; Centre for Addiction and Mental Health, Toronto, Ontario, Canada

  • 6Articles
  • 62KReads
  • 2016–2026Active
  • 45Collaborators
  • 117Citations

About

Tarek K. Rajji, MD, is affiliated with the University of Toronto and the Centre for Addiction and Mental Health in Toronto, Ontario, Canada. His work, published between 2016 and 2026, focuses on topics including cognition, neurology, Alzheimer disease, dementia, geriatric psychiatry, schizophrenia/schizoaffective disorders, and suicide. He has frequently collaborated with Benoit H. Mulsant, Bruce G. Pollock, Ariel Graff-Guerrero, Aristotle N. Voineskos, and David C. Mamo.

Publications

JCP
Neuropsychiatric Symptom Clusters and Brain Structure in Alzheimer’s Disease
Original Research

Neuropsychiatric Symptom Clusters and Brain Structure in Alzheimer’s Disease

March 16, 2026

Neuropsychiatric symptoms in Alzheimer’s disease separate into hyperactivity, psychosis, neurovegetative, and affective clusters, supporting a cluster-based paradigm linking behavioral symptoms with brain structure and functional decline.
, , , et al
JCP
Commentary

Dementia in Older Antidepressant-Treated Adults

August 25, 2020

In this commentary, the authors discuss the article by Bartels and colleagues on the relationship between antidepressant use and risk of incident dementia in older adults.
, ,
JCP
Original Research

Does rTMS Decrease Suicidal Ideation?

April 17, 2018

Read a study on the effects of rTMS on suicidal ideation in patients with treatment-resistant major depression (TRD).
, , , et al
JCP
Original Research

Anticholinergic Burden and Cognition in Schizophrenia

November 28, 2017

Due to the likelihood of their taking multiple medications, older persons with schizophrenia often have a high anticholinergic burden. Read this article to learn the extent to which high...
, , , et al
JCP
Original Research

Insight Into Schizophrenia in Earlier and Later Life

April 26, 2017

Over half of patients with schizophrenia experience impaired insight into their illness, which often contributes to negative outcomes. Here, increase your own insight into predicting which of your patients...
, , , et al
JCP
Article

Hyperprolactinemia in Older Patients With Schizophrenia

December 28, 2016

Since older patients are known to be hypersensitive to antipsychotics, are they vulnerable to developing hyperprolactinemia with these drugs? This post hoc study looked at whether the dopamine D2/3...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe